Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Recursion Pharmaceuticals, Inc. (RXRX : NSDQ)
 
 • Company Description   
Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

Number of Employees: 600

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.70 Daily Weekly Monthly
20 Day Moving Average: 30,684,180 shares
Shares Outstanding: 535.34 (millions)
Market Capitalization: $1,980.77 (millions)
Beta: 1.04
52 Week High: $6.50
52 Week Low: $2.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.88% -3.88%
12 Week 21.71% 18.74%
Year To Date -9.53% -21.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
41S RIO GRANDE STREET
-
SALT LAKE CITY,UT 84101
USA		 ph: 385-269-0203
fax: 801-821-2872		 investor@recursion.com http://www.recursion.com
 
 • General Corporate Information   
Officers
Najat Khan - Chief Executive Officer and Director
Christopher Gibson - Chair of the Board
Robert Hershberg - Vice-chair
Ben Taylor - Chief Financial Officer
Blake Borgeson - Director

Peer Information
Recursion Pharmaceuticals, Inc. (CORR.)
Recursion Pharmaceuticals, Inc. (RSPI)
Recursion Pharmaceuticals, Inc. (CGXP)
Recursion Pharmaceuticals, Inc. (BGEN)
Recursion Pharmaceuticals, Inc. (GTBP)
Recursion Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75629V104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/04/26
Share - Related Items
Shares Outstanding: 535.34
Most Recent Split Date: (:1)
Beta: 1.04
Market Capitalization: $1,980.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.93 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 14.50% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.16
Price/Cash Flow: -
Price / Sales: 36.11
EPS Growth
vs. Year Ago Period: 39.02%
vs. Previous Quarter: -13.64%
Sales Growth
vs. Year Ago Period: -60.10%
vs. Previous Quarter: 18.51%
ROE
09/30/26 - -
06/30/26 - -50.41
03/31/26 - -54.33
ROA
09/30/26 - -
06/30/26 - -38.25
03/31/26 - -40.60
Current Ratio
09/30/26 - -
06/30/26 - 5.03
03/31/26 - 5.47
Quick Ratio
09/30/26 - -
06/30/26 - 5.03
03/31/26 - 5.47
Operating Margin
09/30/26 - -
06/30/26 - -945.94
03/31/26 - -842.95
Net Margin
09/30/26 - -
06/30/26 - -945.94
03/31/26 - -842.95
Pre-Tax Margin
09/30/26 - -
06/30/26 - -954.29
03/31/26 - -849.85
Book Value
09/30/26 - -
06/30/26 - 1.71
03/31/26 - 1.93
Inventory Turnover
09/30/26 - -
06/30/26 - -
03/31/26 - -
Debt-to-Equity
09/30/26 - -
06/30/26 - 0.01
03/31/26 - 0.01
Debt-to-Capital
09/30/26 - -
06/30/26 - 0.52
03/31/26 - 0.70
 

Powered by Zacks Investment Research ©